455 Mission Bay Boulevard South
Tel: 415-482-5300, Toll Free 855-482-NKTR (6587)
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
397 articles with Nektar Therapeutics
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Nektar Therapeutics presented preclinical data on its immuno-oncology pipeline candidates, bempegaldesleukin, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019.
Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019
Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference
Nektar Therapeutics announced that its Chief Scientific Officer, Jonathan Zalevsky, Ph.D., is scheduled to present at the Cowen and Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 9:20 a.m. Eastern Time.
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced the addition of Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the USA and Canada, and Pfizer Inc. (NYSE: PFE) to its Nektar Therapeutics (Nasdaq: NKTR) clinical collaboration to evaluate a novel triple combination therapy in pancreatic cancer.
Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting
Nektar Therapeutics announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study evaluating the safety and efficacy of NKTR-262, a novel toll-like receptor 7/8 agonist, in combination with bempegaldesleukin*, a CD122-preferential IL-2 pathway agonist.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018.
Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Nektar Therapeutics announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin*, a CD122-preferential IL-2 pathway agonist, and NKTR-255, an IL-15 receptor agonist, at the American Association for Cancer Research Annual Meeting 2019, which is being held from March 29 to April 3, 2019 at the Georgia World Congress Center in Atlanta, Georgia.
Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Nektar Therapeutics announced that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2018, on Thursday, February 28, 2019, after the close of U.S.-based financial markets.
Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium
Analyst conference call with urothelial cancer specialist to be held at 2:00 p.m. Pacific Time
The American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU) is being held in San Francisco from February 14-16. Ahead of the conference, several companies have announced presentations. Here’s a look at just a few.
Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium
Nektar Therapeutics announced that it will webcast an analyst and investor conference call with a urothelial cancer specialist and company management on Friday, February 15, 2019 at 2:00 p.m. Pacific Time
Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Ac...
2/8/2019Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.
Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate. On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer AG for infringing a patent for Adynovate.
According to a BioSpace Community Survey, almost 70% of life sciences professionals plan to look for a new job in the next 12 months. Don't delay, accelerate your job search and check out top companies who are looking for quality candidates in 2019!
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!